UK Evidence and Guidance Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management
Beyond weight loss, preclinical and clinical studies have documented anti-inflammatory, antifibrotic, and adipose remodeling properties, including increased Uncoupling Protein-1 (UCP1) mediated thermogenesis through activation of beige adipocytes and restoration of mitochondrial efficiency., which directly overlap with lipedemas pathogenic mechanisms [21,24,25,26,27,28]
This may help you feel fuller, slow down digestion, and lower blood sugar in the process
For convenience and quick guidance, telehealth platforms, particularly those that integrate evidence-based AI assessment with clinician follow-up, are increasingly popular